{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T21:18:54Z","timestamp":1787951934434,"version":"build-2784847793"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ijgc.2025.102815","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T22:03:30Z","timestamp":1763762610000},"page":"102815","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immune landscape and potential role of immune checkpoint inhibitors on uterine leiomyosarcoma: a review"],"prefix":"10.1016","volume":"36","author":[{"given":"Fulvio","family":"Borella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccol\u00f2","family":"Gallio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3625-1285","authenticated-orcid":false,"given":"Domenico","family":"Ferraioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Cosma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ijgc.2025.102815_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.101992","article-title":"Uterine leiomyosarcoma","volume":"35","author":"Bogani","year":"2025","journal-title":"Int J Gynecol Cancer"},{"issue":"10","key":"10.1016\/j.ijgc.2025.102815_bib2","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1136\/ijgc-2024-005823","article-title":"ESGO\/EURACAN\/GCIG guidelines for the management of patients with uterine sarcomas","volume":"34","author":"Ray-Coquard","year":"2024","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijgc.2025.102815_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1482728","article-title":"Autoimmune disease: a view of epigenetics and therapeutic targeting","volume":"15","author":"Mu","year":"2024","journal-title":"Front Immunol"},{"issue":"9916","key":"10.1016\/j.ijgc.2025.102815_bib4","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S0140-6736(13)62226-6","article-title":"Rethinking the war on cancer","volume":"383","author":"Hanahan","year":"2014","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ijgc.2025.102815_bib5","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.cell.2016.01.049","article-title":"The basis of oncoimmunology","volume":"164","author":"Palucka","year":"2016","journal-title":"Cell"},{"issue":"7637","key":"10.1016\/j.ijgc.2025.102815_bib6","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"issue":"6230","key":"10.1016\/j.ijgc.2025.102815_bib7","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"issue":"17","key":"10.1016\/j.ijgc.2025.102815_bib8","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.3390\/cancers13174317","article-title":"Comprehensively exploring the mutational landscape and patterns of genomic evolution in hypermutated cancers","volume":"13","author":"Lin","year":"2021","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.ijgc.2025.102815_bib9","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1158\/0008-5472.CAN-16-2490","article-title":"Systematic pan-cancer analysis reveals immune cell interactions in the tumor microenvironment","volume":"77","author":"Varn","year":"2017","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102815_bib10","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/s41467-018-03730-x","article-title":"Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancers","volume":"9","author":"McGrail","year":"2018","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.ijgc.2025.102815_bib11","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nri3920","article-title":"Regulation of macrophage development and function in peripheral tissues","volume":"15","author":"Lavin","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102815_bib12","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/s41598-020-57627-1","article-title":"The adaptive and innate immune cell landscape of uterine leiomyosarcomas","volume":"10","author":"Manzoni","year":"2020","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.ijgc.2025.102815_bib13","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1097\/PAS.0000000000001254","article-title":"PD-L1 expression and tumor-infiltrating lymphocytes in uterine smooth muscle tumors: implications for immunotherapy","volume":"43","author":"Shanes","year":"2019","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102815_bib14","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.1038\/s41467-021-24677-6","article-title":"Lineage-defined leiomyosarcoma subtypes emerge years before diagnosis and determine patient survival","volume":"12","author":"Anderson","year":"2021","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.ijgc.2025.102815_bib15","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.3390\/cancers15072099","article-title":"Targeting the molecular and immunologic features of leiomyosarcoma","volume":"15","author":"Cope","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102815_bib16","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1038\/s41467-022-30453-x","article-title":"Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets","volume":"13","author":"Nacev","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102815_bib17","first-page":"441","article-title":"Cancer-testis antigens are predominantly expressed in uterine leiomyosarcoma compared with non-uterine leiomyosarcoma","volume":"15","author":"Iura","year":"2018","journal-title":"Oncol Lett"},{"issue":"14","key":"10.1016\/j.ijgc.2025.102815_bib18","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.3390\/cancers15143705","article-title":"Comprehensive immune profiling unveils a subset of leiomyosarcoma with \u201chot\u201d tumor immune microenvironment","volume":"15","author":"Feng","year":"2023","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102815_bib19","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1386828","article-title":"Increased infiltration of M2-macrophages, T-cells and PD-L1 expression in high grade leiomyosarcomas supports immunotherapeutic strategies","volume":"7","author":"Kostine","year":"2017","journal-title":"Oncoimmunology"},{"issue":"11","key":"10.1016\/j.ijgc.2025.102815_bib20","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.4161\/21645515.2014.983003","article-title":"Potential for immunotherapy in soft tissue sarcoma","volume":"10","author":"Tseng","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102815_bib21","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s11523-025-01145-5","article-title":"Potential mechanisms for immunotherapy resistance in adult soft-tissue sarcoma","volume":"20","author":"Kret","year":"2025","journal-title":"Target Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102815_bib22","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3892\/or.2020.7837","article-title":"PD-L1 and IDO-1 expression in undifferentiated pleomorphic sarcoma: the associations with tumor infiltrating lymphocytes, dMMR and HLA class I","volume":"45","author":"Ishihara","year":"2021","journal-title":"Oncol Rep"},{"issue":"21","key":"10.1016\/j.ijgc.2025.102815_bib23","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.3390\/cancers15215294","article-title":"The role of macrophages in sarcoma tumor microenvironment and treatment","volume":"15","author":"Zaj\u0105c","year":"2023","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.ijgc.2025.102815_bib24","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/intimm\/dxac014","article-title":"lncRNA EGFR-AS1 facilitates leiomyosarcoma progression and immune escape via the EGFR-MYC-PD-L1 axis","volume":"34","author":"Chen","year":"2022","journal-title":"Int Immunol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102815_bib25","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3390\/diagnostics10030146","article-title":"Immune checkpoint inhibitors in epithelial ovarian cancer: an overview on efficacy and future perspectives","volume":"10","author":"Borella","year":"2020","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.ijgc.2025.102815_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114070","article-title":"Efficacy of immune checkpoint inhibitors in the treatment of soft tissue sarcoma: a systematic review and meta-analysis of clinical trials","volume":"148","author":"Cao","year":"2025","journal-title":"Int Immunopharmacol"},{"issue":"17","key":"10.1016\/j.ijgc.2025.102815_bib27","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1002\/cncr.30738","article-title":"Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: results of a phase 2 study","volume":"123","author":"Ben-Ami","year":"2017","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102815_bib28","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.immuni.2017.02.001","article-title":"Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma","volume":"46","author":"George","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.ijgc.2025.102815_bib29","article-title":"Use of pembrolizumab in MSI-high uterine leiomyosarcoma; a case report and review of the literature","volume":"35","author":"Wang","year":"2021","journal-title":"Gynecol Oncol Rep"},{"issue":"11","key":"10.1016\/j.ijgc.2025.102815_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2023-256697","article-title":"PD-1 Inhibition in metastatic high tumour mutational burden (TMB) leiomyosarcoma with clinicopathological correlates","volume":"16","author":"Pandita","year":"2023","journal-title":"BMJ Case Rep"},{"issue":"11","key":"10.1016\/j.ijgc.2025.102815_bib31","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003156","article-title":"Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209-538 clinical trial","volume":"9","author":"Klein","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"11","key":"10.1016\/j.ijgc.2025.102815_bib32","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1200\/JCO-24-02524","article-title":"Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients with Relapsed\/Refractory Metastatic Sarcomas","volume":"43","author":"Wilky","year":"2025","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102815_bib33","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1200\/JCO.24.00358","article-title":"Phase Ib study for the combination of doxorubicin, dacarbazine, and nivolumab as the upfront treatment in patients with advanced leiomyosarcoma: a study by the Spanish sarcoma group (GEIS)","volume":"43","author":"Martin-Broto","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102815_bib34","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1001\/jamaoncol.2017.1617","article-title":"Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas: a phase 2 clinical trial","volume":"4","author":"Toulmonde","year":"2018","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.ijgc.2025.102815_bib35","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1158\/1078-0432.CCR-22-0240","article-title":"A phase 1\/2 trial combining avelumab and trabectedin for advanced liposarcoma and leiomyosarcoma","volume":"28","author":"Wagner","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijgc.2025.102815_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2021.08.856","article-title":"1526MO GEMMK: a phase I study of gemcitabine (gem) and pembrolizumab (pem) in patients (pts) with leiomyosarcoma (LMS) and undifferentiated pleomorphic sarcoma UPS)","volume":"32","author":"Smrke","year":"2021","journal-title":"Ann Oncol"},{"issue":"suppl 17","key":"10.1016\/j.ijgc.2025.102815_bib37","doi-asserted-by":"crossref","first-page":"LBA11504","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA11504","article-title":"Randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition versus cabozantinib in metastatic soft tissue sarcoma","volume":"41","author":"Van Tine","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijgc.2025.102815_bib38","article-title":"A promising response of refractory uterine leiomyosarcoma to pembrolizumab and temozolomide combination therapy","volume":"51","author":"Lin","year":"2024","journal-title":"Gynecol Oncol Rep"},{"key":"10.1016\/j.ijgc.2025.102815_bib39","article-title":"A case of pembrolizumab and lenvatinib as an alternative therapy for leiomyosarcoma","volume":"45","author":"Mehta","year":"2023","journal-title":"Gynecol Oncol Rep"},{"key":"10.1016\/j.ijgc.2025.102815_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1116937","article-title":"Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas (NCT# 03886311)","volume":"13","author":"Chawla","year":"2023","journal-title":"Front Oncol"},{"issue":"10","key":"10.1016\/j.ijgc.2025.102815_bib41","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s11912-025-01706-x","article-title":"Adoptive T-cell therapy in sarcomas","volume":"27","author":"Kucharczyk","year":"2025","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102815_bib42","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13045-023-01492-8","article-title":"Challenges and new technologies in adoptive cell therapy","volume":"16","author":"Zhang","year":"2023","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ijgc.2025.102815_bib43","article-title":"Regional and intratumoral adoptive T-cell therapy","volume":"24","author":"Olivera","year":"2024","journal-title":"Immunooncol Technol"},{"issue":"7","key":"10.1016\/j.ijgc.2025.102815_bib44","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1038\/s41591-025-03650-6","article-title":"Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A\u221702(+) patients: a phase 1 trial","volume":"31","author":"Wermke","year":"2025","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.ijgc.2025.102815_bib45","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.3390\/cancers17081302","article-title":"Review of adoptive cellular therapies for the treatment of sarcoma","volume":"17","author":"Fradin","year":"2025","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102815_bib46","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2023.2290900","article-title":"LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes generate tumor specific T cells in patients with metastatic soft tissue sarcoma","volume":"13","author":"Nielsen","year":"2023","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102815_bib47","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70140","article-title":"Enhancement of anti-sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2-targeted CAR","volume":"15","author":"Lam","year":"2025","journal-title":"Clin Transl Med"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102815_bib48","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1186\/s12885-024-13061-4","article-title":"B7-H3 is widely expressed in soft tissue sarcomas","volume":"24","author":"Lynch","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijgc.2025.102815_bib49","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13569-017-0077-3","article-title":"Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes","volume":"7","author":"Roszik","year":"2017","journal-title":"Clin Sarcoma Res"},{"issue":"9","key":"10.1016\/j.ijgc.2025.102815_bib50","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.3390\/cancers13092040","article-title":"Resistance to immune checkpoint blockade in uterine leiomyosarcoma: what can we learn from other cancer types?","volume":"13","author":"De Wispelaere","year":"2021","journal-title":"Cancers"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25019371?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25019371?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T20:36:31Z","timestamp":1787949391000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X25019371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1048891X25019371"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.102815","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune landscape and potential role of immune checkpoint inhibitors on uterine leiomyosarcoma: a review","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.102815","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of European Society of Gynaecological Oncology and the International Gynecologic Cancer Society.","name":"copyright","label":"Copyright"}],"article-number":"102815"}}